Curis, Inc. (CRIS) AI Stock Analysis
CRIS AI stock analysis summary
AI ResearchCuris, Inc. is a clinical-stage biotechnology company focused on developing drug candidates for human cancers. Over the trailing twelve months ended June 30, 2026, the company generated $4.3M in revenue with an operating margin of -833.4%. Its shares fell 98.7% over the past year, closing at $0.41 with a market capitalization of $987,249.
- Market cap
- $987,249
- Revenue (TTM)
- $4.3M
- P/E
- 0.3x
- 1Y return
- -98.7% S&P 500 16.8%
- Avg. target
- $42.67 10306.5% vs last close
Bull case
- Analysts maintain 3 Strong Buy ratings and 1 Buy rating with a mean price target of $42.67.
- Net cash stood at $4.6M as of June 30, 2026, with total debt limited to $1.0M.
- Annual net losses narrowed from -$43.4M in FY2024 to -$7.6M in FY2025.
Bear case
- The stock declined 98.7% over the past year and trades at $0.41, down 95.9% from its 200-day moving average.
- Quarterly revenue decreased 66.0% year-over-year in the period ended June 30, 2026, while free cash flow was -$27.2M in FY2025.
- Curis had a current ratio of 0.49 as of June 30, 2026, following a 5-year share count expansion of 832.7%.
What Curis does
Curis, Inc. is a biotechnology company based in Lexington, Massachusetts, specializing in the discovery and advancement of novel drug candidates to treat human cancers. Its clinical-stage portfolio is led by Emavusertib, an oral small molecule in Phase 1/2 clinical trials for non-Hodgkin lymphomas, acute myeloid leukemia, and myelodysplastic syndromes. Curis is also developing CI-8993, a monoclonal antibody targeting V-domain Ig suppressor of T cell activation, along with Fimepinostat for diffuse large B-cell lymphoma and CA-170 for advanced solid tumors. Additionally, Curis collaborates with partners including F. Hoffmann-La Roche Ltd. and Genentech Inc. on therapies like Erivedge.
Growth and profitability
Between FY2021 and FY2025, annual revenue fell from $10.6M to $9.4M, reflecting a 5-year compound annual growth rate of -2.7%. In FY2025, revenue contracted 13.4% while gross margin was 99.5%, yielding an operating margin of -348.4% and net income of -$7.6M compared to -$43.4M in FY2024. For the latest quarter ended June 30, 2026, revenue dropped 66.0% year-over-year. Trailing twelve months revenue totaled $4.3M with an operating margin of -833.4% and diluted EPS of $1.32, alongside an annual R&D spend of $28.3M in FY2025.
Balance sheet and cash flow
As of June 30, 2026, Curis held $5.6M in cash and short-term investments against total debt of $1.0M, resulting in net cash of $4.6M. Total assets stood at $19.0M, supporting shareholders' equity of $4.7M and a debt-to-equity ratio of 0.22. However, the current ratio was 0.49, reflecting tight near-term liquidity. Operating cash flow in FY2025 was -$27.2M and free cash flow was -$27.2M. Over five years, the company expanded its share count by 832.7% to support ongoing operations.
Valuation and performance
At $0.41 per share, Curis trades at a trailing price-to-earnings ratio of 0.3x, a price-to-sales ratio of 0.2x, and a price-to-book ratio of 0.6x. These metrics sit well below the median of its US-listed Healthcare peers, which reflect a trailing price-to-earnings ratio of 24.6x, a price-to-sales ratio of 4.1x, and an enterprise value to EBITDA ratio of 12.0x. Over the past year, Curis shares declined 98.7% compared to a 16.8% gain for the S&P 500, and over five years the stock returned -100.0% versus an 83.0% gain for the benchmark.
What analysts expect
Curis carries 3 Strong Buy ratings and 1 Buy rating among Wall Street analysts. The mean price target is $42.67, representing a 10306.5% premium to the last closing price of $0.41. For the current fiscal year ending December 31, 2026, analysts estimate an EPS of -$23.78 and revenue of $0. For the next fiscal year, 3 analysts project revenue of $9.2M and an EPS of -$6.01. The company beat EPS estimates in 2 of the last 4 quarters and is scheduled to report earnings on November 5, 2026.
Key risks and what to watch
- A current ratio of 0.49 indicates working capital pressure against a trailing free cash flow burn of -$27.2M in FY2025.
- The trailing twelve months operating margin of -833.4% reflects large continuing operational losses relative to revenues.
- The stock has a beta of 3.10, indicating significantly higher price volatility than the broader equity market.
- Shareholder value has experienced heavy dilution, with the share count increasing 832.7% over the past five years.
AI-generated research summary. Written with AI from Quotelinks data as of October 16, 2026 and checked so every figure matches that data. For information only, not investment advice. Disclaimer
About this CRIS AI stock analysis
This page is an AI-written research summary of Curis, Inc. (CRIS). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.
Related: CRIS income statement, CRIS balance sheet, CRIS key metrics, CRIS analyst forecast, CRIS chart. See the CRIS stock overview for the latest quote and news.
CRIS AI stock analysis FAQ
What does Curis, Inc. do?
Curis, Inc. is a biotechnology company developing drug candidates to treat human cancers, including clinical-stage candidate Emavusertib.
What is Curis's cash position?
As of June 30, 2026, Curis held $5.6M in cash and short-term investments, with net cash of $4.6M after accounting for $1.0M in total debt.
How has CRIS stock performed relative to the market?
Over the past year, CRIS shares fell 98.7% to close at $0.41, while the S&P 500 gained 16.8%.
When is the next earnings release for Curis?
Curis is scheduled to report its next quarterly financial results on November 5, 2026.